KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Travere Therapeutics (TVTX) over the last 15 years, with Q3 2025 value amounting to $105.8 million.

  • Travere Therapeutics' Accumulated Expenses rose 2603.32% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year increase of 2603.32%. This contributed to the annual value of $86.0 million for FY2024, which is 2770.21% down from last year.
  • As of Q3 2025, Travere Therapeutics' Accumulated Expenses stood at $105.8 million, which was up 2603.32% from $81.7 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Accumulated Expenses high stood at $139.6 million for Q1 2024, and its period low was $46.5 million during Q1 2021.
  • Over the past 5 years, Travere Therapeutics' median Accumulated Expenses value was $83.9 million (recorded in 2024), while the average stood at $85.6 million.
  • As far as peak fluctuations go, Travere Therapeutics' Accumulated Expenses skyrocketed by 6274.51% in 2024, and later tumbled by 4475.71% in 2025.
  • Travere Therapeutics' Accumulated Expenses (Quarter) stood at $75.2 million in 2021, then grew by 27.35% to $95.7 million in 2022, then grew by 24.28% to $119.0 million in 2023, then dropped by 27.7% to $86.0 million in 2024, then increased by 22.94% to $105.8 million in 2025.
  • Its Accumulated Expenses was $105.8 million in Q3 2025, compared to $81.7 million in Q2 2025 and $77.1 million in Q1 2025.